INDSWFTLAB
Ind-Swift Laboratories Limited (INDSWFTLAB) Stock Analysis
Ind-Swift Laboratories Limited manufactures pharmaceutical APIs and formulations for domestic and export markets. It operates in antibiotics and specialty actives for generic drug makers. The company has API plants in India. It is a listed pharma company.
Healthcare › Drug Manufacturers - Specialty & Generic
₹360.90
-8.67% 1W | +249.60% 52W
Market Cap
3.1k CR
P/E Ratio
53.9
52W High
₹424.8
52W Low
₹87.2
Div. Yield
0%
Beta
0.8
50 DMA
₹346.6
200 DMA
₹200.2
Profit Margin
8.5%
Inst. Own.
5.8%
⚠️ BREAKDOWN
⚠️ BREAKDOWN
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 310 | 290 | 288 | 529 | 33 | 12 | 129 | 138 | 153 | 153 | 151 | 170 | 191 |
| Expenses | 250 | 224 | 236 | 437 | 43 | 24 | 135 | 147 | 149 | 151 | 147 | 149 | 158 |
| Operating Profit | 60 | 66 | 52 | 91 | -10 | -12 | -7 | -9 | 4 | 1 | 4 | 21 | 33 |
| OPM % | 19% | 23% | 18% | 17% | -29% | -99% | -5% | -7% | 2.4% | 1.0% | 2.8% | 12% | 17% |
| Other Income | 6 | 7 | 7 | 458 | 11 | 13 | 16 | 220 | 15 | 18 | 22 | -3 | 7 |
| Interest | 20 | 21 | 21 | 3 | 0 | 0 | 10 | -27 | 1 | 2 | 1 | -2 | 1 |
| Depreciation | 14 | 13 | 14 | 20 | 0 | 0 | 6 | 7 | 7 | 7 | 9 | 8 | 8 |
| Profit before tax | 32 | 39 | 24 | 527 | 1 | 1 | -7 | 230 | 10 | 10 | 16 | 12 | 33 |
| Tax % | 45% | 18% | 19% | 6% | -3% | 31% | -16% | 4% | 17% | 22% | 42% | -26% | 25% |
| Net Profit | 17 | 32 | 19 | 494 | 1 | 0 | -5 | 222 | 9 | 8 | 10 | 15 | 25 |
| EPS in Rs | 2.92 | 5.36 | 3.29 | 83.55 | 0.16 | 0.07 | -0.93 | 36.67 | 1.45 | 0.98 | 1.17 | 1.74 | 2.84 |
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 660 | 653 | 716 | 765 | 757 | 780 | 891 | 1,039 | 1,207 | 1,281 | 574 | 649 | 665 |
| Expenses | 571 | 546 | 610 | 631 | 630 | 635 | 709 | 837 | 978 | 1,029 | 581 | 602 | 605 |
| Operating Profit | 89 | 107 | 106 | 134 | 126 | 144 | 183 | 202 | 229 | 252 | -7 | 47 | 60 |
| OPM % | 13% | 16% | 15% | 18% | 17% | 19% | 21% | 19% | 19% | 20% | -1.2% | 7% | 9% |
| Other Income | -31 | 1 | 15 | 16 | 120 | 33 | 23 | 37 | 7 | 434 | 292 | 36 | 44 |
| Interest | 117 | 106 | 88 | 28 | 92 | 107 | 100 | 96 | 92 | 51 | 3 | 1 | 1 |
| Depreciation | 84 | 85 | 88 | 87 | 104 | 90 | 87 | 131 | 57 | 53 | 24 | 31 | 32 |
| Profit before tax | -143 | -83 | -55 | 36 | 50 | -20 | 18 | 13 | 87 | 582 | 258 | 51 | 71 |
| Tax % | -17% | -29% | -29% | 39% | 42% | 7% | 117% | 117% | 45% | 28% | 3% | 15% | |
| Net Profit | -119 | -59 | -39 | 22 | 29 | -21 | -3 | -2 | 48 | 421 | 250 | 43 | 57 |
| EPS in Rs | -29.14 | -14.33 | -8.75 | 4.85 | 6.09 | -3.59 | -0.53 | -0.36 | 8.06 | 71.24 | 41.32 | 4.97 | 6.73 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | -19.0% | -6.0% | 0.0% |
| Profit CAGR | -6.0% | 79.0% | 12.0% |
Shareholding Pattern
Promoters39.49%
FIIs14.80%
DIIs0.68%
Public45.02%
Promoters39.49%
FIIs14.33%
DIIs0.68%
Public45.50%
Promoters43.00%
FIIs13.88%
Public43.14%
Promoters42.93%
FIIs10.70%
DIIs0.17%
Public46.19%
Promoters42.93%
FIIs10.90%
DIIs0.15%
Public46.01%
Promoters42.01%
DIIs19.49%
Public38.52%
Promoters42.01%
FIIs0.26%
DIIs8.03%
Public49.72%
Promoters40.94%
FIIs3.07%
DIIs0.91%
Public55.08%
Promoters43.00%
FIIs13.88%
Public43.14%
Promoters42.93%
FIIs10.90%
DIIs0.15%
Public46.01%
INDSWFTLAB
Holdings Analysis
Key strengths & risk signals
59
Overall
39
Fundamental
79
Technical
Risks (2)
Cannot calculate PEG - insufficient growth data.
WEAK MOMENTUM! Limited price growth - -8.7% (1 week), -7.1% (1 month), 46.5% (3 months).
Strengths (4)
GOOD STABILITY! Only 1 revenue dip in history. Strong business fundamentals.
BULLISH TREND! 50-day average (346.6) is above 200-day average (200.2) - positive signal.
EXCELLENT YEAR! Stock gained 249.6% in the last year.
STRONG! Trading at 81.1% of 52W range - near yearly highs.
Fundamental & Technical Analysis
59Overall
39Fundamental
79Technical
Fundamental Breakdown
Growth Quality
4/30
Revenue CAGR: -19.7% (DECLINING, 2/15). Profit CAGR: -3.2% (DECLINING, 2/15).
Profit Margin
3/10
LOW MARGIN! 8.5% profit margin - thin profits.
PEG Valuation
1/10
Cannot calculate PEG - insufficient growth data.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
10/20
SIGNIFICANT PUBLIC HOLDING! 38.44% public ownership - moderate retail influence.
Stability Index
8/10
GOOD STABILITY! Only 1 revenue dip in history. Strong business fundamentals.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (346.6) is above 200-day average (200.2) - positive signal.
Price Position
8/10
STRONG POSITION! Current price (360.9) is above both moving averages.
Trend Pattern
10/20
BREAKDOWN! Stock has broken below support levels - weakness present.
52W Performance
10/10
EXCELLENT YEAR! Stock gained 249.6% in the last year.
Volume Sentiment
25/30
BULLISH SENTIMENT! In last 30 days: 16 up days, 14 down days. Avg volume on up days: 816,417 vs down days: 637,233. Ratio: 1.28x
RSI
3/5
NEUTRAL! RSI at 45.8 - balanced momentum.
52W Range
5/5
STRONG! Trading at 81.1% of 52W range - near yearly highs.
Momentum
2/5
WEAK MOMENTUM! Limited price growth - -8.7% (1 week), -7.1% (1 month), 46.5% (3 months).
Beta
4/5
BELOW MARKET! Beta of 0.80 - slightly less volatile than market.
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| INDSWFTLAB | ₹360.90 | 53.9 | 8.5% | -19.7% | -3.2% | +249.6% | 59 | BREAKDOWN | +180.7% | +63.6% | +21.0% | +12.8% |
| SOLARA | ₹644.40 | – | -0.1% | -1.2% | – | +14.8% | 53 | CONSOLIDATING DOWN | +55.2% | +69.8% | +19.5% | -1.5% |
| HIKAL | ₹213.70 | – | -1.9% | -5.4% | – | -9.2% | 52 | CONSOLIDATING DOWN | -67.0% | -151.4% | +7.7% | -22.7% |
| UNICHEMLAB | ₹531.10 | 12.3 | 13.2% | 18.4% | – | +12.3% | 64 | BREAKDOWN | -495.2% | +280.7% | +20.1% | +10.0% |
| AARTIDRUGS | ₹413.30 | 19.7 | 7.1% | -2.3% | 5.4% | -17.9% | 57 | BOUNCE FROM SUPPORT | -6.9% | -9.1% | +19.0% | -2.4% |
| SAKAR | ₹1,011.50 | 72.3 | 13.3% | 22.0% | 23.0% | +184.6% | 78 | BREAKDOWN | +112.8% | -9.1% | +38.5% | +2.7% |
| SYNCOMF | ₹23.30 | 24.8 | 17.2% | 29.4% | 56.2% | +38.7% | 84 | BREAKOUT | +57.0% | -1.6% | +7.4% | -7.3% |
| VENUSREM | ₹1,719.50 | 22.4 | 13.4% | 11.6% | 57.0% | +264.9% | 74 | BREAKDOWN | +126.2% | +85.5% | +31.2% | +43.9% |
Data from TradeAlone · Updated daily
